Table 1 Pretreatment patient characteristics

No. of patients

29

Follow-up period median (range)

26.8 (2.7–86.5)

Gender (male/female)

28/1

Age median (range)

73 (62–90)

Performance Status (ECOG) 0/1/2/3

15/13/2/0

Smoking history (pack years) median (range)

42 (0–210)

Severity of ILD (grade 1/2/3/4)

9/10/6/4

Dyspnea evaluation before CIRT

 No. of patients using home oxygen therapy

4

 mMRC scale (grade 0/1/2/3/4)

0/11/6/8/4

 equivalent RP grade CTCAE ver 3.0 (grade 1/2/3/4/5)

11/14/4/0/0

 %FVC median (range)^a

82.3 (37.9–117.6)

 %DLco median (range)^a

52.1 (15.5–235.5)

Tumor size

34 (17–63)

 T1a (≤2 cm)

2

 T1b (2-3 cm)

8

 T2a (3-5 cm)

14

 T2b (≥5 cm)

5

Tumor location

3000

 Upper lobe (including 2 tumors in middle lobe)

15

 Lower lobe

14

Nodal involvement (yes/no/suspected)

2/23/4

 Location of nodal involvement of 2 patients

#11 (left hilar lymph node)

 Adenocarcinoma

8

 Squamous cell carcinoma

10

 Unclassified non-small cell carcinoma

2

 Clinically diagnosed

9

 serum KL-6 (U/l) median (range)

1167 (456–2410)

 serum SP-D (ng/l) median (range)

157 (31–502)

 at the same time as lung cancer diagnosis

14

 unknown

1

 before diagnosis of lung cancer

14

Period from ILD to cancer diagnosis (median years) (range)

4 (2–13)

Episode of acute exacerbation before treatment (yes/no)

4/25

Auto-immune disease (yes/no)

4/25